Do I need an in-person exam for Mounjaro in Florida?

If you’ve been wondering whether it’s possible to access prescription weight loss medications like Wegovy, Ozempic, or Mounjaro through a virtual visit instead of scheduling an in-person appointment, you’re not alone. With telehealth becoming a mainstream option for healthcare—and with the skyrocketing demand for GLP-1 medications—many people are asking: Can I legally get weight loss medication through telehealth?

The short answer is yes—in most cases, you can. But the details matter, especially when it comes to understanding federal rules, state-specific requirements, and what to expect from a legitimate telehealth provider. This guide will walk you through everything you need to know about getting weight loss medication through telehealth in 2025, including how it works, which states have special requirements, and how to ensure you’re working with a safe, compliant provider.

Understanding the Legal Landscape: Federal Rules for Telehealth Prescribing

One of the most common questions about telehealth weight loss treatment centers on federal law—specifically, whether you need an in-person visit before a provider can prescribe medication. Here’s the key distinction that clears up much of the confusion:

GLP-1 weight loss medications like Wegovy, Ozempic, and Mounjaro are not controlled substances. This is crucial because federal law (the Ryan Haight Act) only requires an in-person exam for controlled medications like Adderall, opioids, or certain anxiety medications. Since semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro/Zepbound) are unscheduled drugs, there is no federal requirement for an in-person visit before prescribing them via telehealth.

During the COVID-19 pandemic, the DEA temporarily waived the in-person requirement even for controlled substances to expand access to care. As of December 2025, those flexibilities have been extended through the end of the year—but this extension primarily affects medications like ADHD stimulants or buprenorphine for opioid use disorder, not GLP-1 weight loss drugs, which were never restricted federally in the first place.

Bottom line: Under federal law, a licensed healthcare provider can evaluate you via telehealth (typically through a live video visit) and send a prescription for a GLP-1 medication to your pharmacy electronically—no in-person appointment required at the federal level.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-Specific Rules: Where Telehealth Weight Loss Prescribing Gets Complex

While federal law is permissive, each state has the authority to set its own standards for telehealth practice and prescribing. Some states have embraced fully remote weight loss treatment, while others impose additional requirements—most commonly an initial in-person exam or periodic check-ins.

States Requiring an Initial In-Person Visit

Several states mandate that patients have at least one in-person physical examination before (or shortly after) starting telehealth-based weight loss medication. These include:

• Arkansas: One of the most restrictive states for telemedicine, Arkansas requires an in-person exam to establish the patient-provider relationship before prescribing weight loss medications.
• Delaware: An initial physical exam must be completed in person before telehealth prescribing can begin.
• Georgia: State policy requires an in-person exam prior to prescribing obesity medications via telehealth (though new 2024 legislation expanded NP/PA prescribing authority for other drug classes).
• Mississippi: Requires an initial in-person evaluation for weight management therapy.
• New Jersey: Among the strictest—state medical board rules mandate a comprehensive initial exam including physical assessment, lab work, and psychological screening before prescribing any weight-loss drug.
• North Dakota: Expects a hands-on initial evaluation for weight-loss treatment per state medical board guidance.
• South Carolina: State obesity treatment policy requires an initial in-person visit before telehealth can be used for ongoing care.
• Texas: While telehealth is broadly permitted, the standard of care typically requires an initial in-person exam for weight loss medication. Texas also has strict oversight of NP/PA prescribing (they must work under physician agreements).
• Utah: Encourages an initial in-person exam, though telehealth follow-ups are widely accepted.
• Virginia: State Board of Medicine rules require an initial physical exam, lab tests, and a personalized diet/exercise plan before prescribing weight-loss medications. Follow-up within 30 days of starting therapy is also mandated.

States With No In-Person Requirement

Many states have no specific mandate for an initial in-person visit for weight loss medications, meaning telehealth-only treatment is fully permitted as long as the provider establishes a proper patient relationship (usually via live video consultation). These include:

• California: Explicitly permits telehealth exams as sufficient; no in-person requirement. NPs have full independent practice authority.
• Connecticut: No in-person mandate. However, state rules require behavioral counseling and diet/exercise plans as part of obesity treatment.
• Florida: No in-person requirement at the state level for telehealth prescribing. Florida does mandate that patients have a BMI ≥30 and be seen at least every 3 months during treatment.
• Illinois: Permanent telehealth law with no special in-person rules for weight loss medications.
• New York: Telehealth exam is sufficient; no in-person mandate. NPs practice independently after gaining experience.
• Pennsylvania: No in-person barrier for GLP-1 prescribing via telehealth.
• Washington: A pioneer in telehealth with no in-person requirements. Full NP independence. The state’s My Health My Data Act (2023) does impose strict patient privacy protections for sensitive health information.

Important note: Even in states without specific in-person requirements, reputable telehealth providers will conduct thorough evaluations (detailed medical history, current medications, baseline vitals) and may request lab work or periodic check-ins to ensure treatment safety. The lack of a legal in-person requirement doesn’t mean corners are cut—it means the exam can happen virtually.

Who Can Prescribe Weight Loss Medications via Telehealth?

Another key consideration is who your telehealth provider will be. All states allow licensed physicians (MDs and DOs) to prescribe GLP-1 medications via telehealth, assuming they’re licensed in the state where you’re located. But what about Nurse Practitioners (NPs) and Physician Assistants (PAs)?

Nurse Practitioner and PA Authority

As of 2025, 34 states plus Washington D.C. grant NPs full independent practice authority, meaning they can diagnose, treat, and prescribe medications (including weight loss drugs) without physician oversight. In these states, it’s perfectly normal—and legal—to have your entire telehealth weight loss treatment managed by an NP.

States with independent NP practice include California, New York, Washington, Arizona, Connecticut, Colorado, Maryland, and many others. NPs in these states can open their own practices and prescribe any FDA-approved medication within their scope.

Other states require collaborative agreements or physician supervision for NPs and PAs to prescribe. For example:

• Texas: NPs and PAs must have formal agreements with supervising physicians. They can prescribe GLP-1s but have restrictions on controlled substances.
• Florida: NPs have limited autonomy (primarily in primary care settings); obesity specialty prescribing typically requires physician collaboration.
• Pennsylvania: NPs still operate under physician collaborative agreements as of 2025, though independence legislation has been proposed.
• Georgia: Recent 2024 legislation (HB557) now allows NPs and PAs to prescribe even Schedule II controlled drugs with physician delegation—a significant expansion, though collaboration is still required.

Key takeaway: Whether you see an MD, DO, NP, or PA through telehealth, rest assured they are operating within their state’s legal framework. At Klarity Health, all providers are appropriately licensed and credentialed in the states where they practice, ensuring you receive care from qualified professionals who meet all regulatory requirements.

What to Expect from a Legitimate Telehealth Weight Loss Program

Understanding how the process works—and what separates a high-quality service from questionable options—is essential. Here’s what you should expect when seeking weight loss medication through telehealth:

1. Comprehensive Medical Evaluation

A legitimate telehealth provider will never guarantee you a prescription upfront. Instead, the process starts with a thorough intake:

• Detailed health questionnaire: Expect questions about your weight history, previous weight loss attempts, current medications, medical conditions (especially thyroid issues, gallbladder disease, history of pancreatitis), family history of thyroid cancer, and mental health.
• Live video consultation: Most states require a ‘synchronous’ (real-time) visit via video to establish the patient-provider relationship. During this visit, your provider will review your health history, discuss your weight loss goals, calculate your BMI, and assess whether you’re a candidate for medication.
• Baseline measurements: You’ll provide current height and weight (some programs ask for verification, such as a photo of your scale or measurements taken at a local pharmacy). Your provider will calculate your BMI to confirm eligibility (typically BMI ≥30, or ≥27 with weight-related health conditions like prediabetes, hypertension, or sleep apnea).

2. Medication Eligibility Criteria

GLP-1 medications are powerful therapies indicated for chronic weight management in specific populations. To qualify, you generally must:

• Be an adult (18+)
• Have a BMI of 30 or higher (clinical obesity), OR
• Have a BMI of 27 or higher with at least one weight-related comorbidity (type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea)
• Have attempted lifestyle modifications (diet and exercise) without achieving adequate weight loss (unless medically inadvisable)
• Have no contraindications, including:
• Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)—all GLP-1s carry an FDA boxed warning for thyroid C-cell tumors
• Pregnancy or plans to become pregnant (must discontinue medication at least 2 months before conception)
• Active gallbladder disease
• History of severe pancreatitis
• Severe gastrointestinal disorders (e.g., gastroparesis)

3. Treatment Plan and Informed Consent

If you’re deemed eligible, your provider will create a personalized treatment plan that includes:

• Medication selection and dosing: Starting with a low dose to minimize side effects, with gradual titration over weeks or months.
• Lifestyle counseling: Emphasis on nutrition, physical activity, and behavioral changes to support sustainable weight loss. Some states (like Connecticut and Virginia) legally require this counseling component.
• Informed consent: Discussion of potential side effects (nausea, vomiting, diarrhea, constipation, risk of gallstones, rare cases of pancreatitis), how to administer injections, and what to do if side effects occur.
• Follow-up schedule: Regular check-ins (often monthly initially, then every 2-3 months) to monitor progress, adjust dosing, and ensure safety.

4. Electronic Prescription to Your Pharmacy

Once approved, your prescription will be sent electronically to the pharmacy of your choice. Many states now require e-prescribing for all medications. The prescription will typically be:

• Initial supply: Often 4 weeks to assess tolerance
• Refills or ongoing prescriptions: After the initial trial, prescriptions may be written for 1-3 months at a time, depending on state rules and your provider’s protocol

Insurance vs. cash pay: Klarity Health works with both insurance and cash-pay patients. If you have insurance, we’ll work to verify coverage and submit prescriptions accordingly. GLP-1 medications can be expensive without insurance (often $1,000+ per month), though some manufacturers offer savings programs. If paying cash, we provide transparent pricing upfront so there are no surprises.

5. Ongoing Monitoring and Support

Weight loss medication is not a ‘set it and forget it’ treatment. Reputable providers will:

• Schedule periodic follow-ups (some states mandate specific intervals—Florida requires visits at least every 3 months, Virginia within 30 days of starting)
• Monitor for side effects and adjust treatment as needed
• Track weight loss progress and celebrate milestones
• Provide access to support between visits (messaging, phone consults) if questions or concerns arise
• Order lab work when appropriate (e.g., metabolic panels, A1C if diabetic, lipid panels)

Medications Available Through Telehealth

Let’s look at the three most commonly prescribed GLP-1 medications for weight loss and what you need to know about each:

Wegovy (Semaglutide 2.4 mg)

• FDA approval: Specifically approved for chronic weight management in adults with obesity or overweight with comorbidities
• Dosing: Once-weekly subcutaneous injection, starting at 0.25 mg and gradually increasing to 2.4 mg maintenance dose
• Expected results: Average weight loss of 15-20% of body weight over 68 weeks in clinical trials
• Notes: Should be prescribed alongside lifestyle intervention. FDA ended the shortage declaration in 2024, but supply can still be variable. Compounded versions are generally prohibited as of May 2025.

Ozempic (Semaglutide 0.5-1 mg)

• FDA approval: Approved for type 2 diabetes management
• Off-label use: Widely prescribed off-label for weight loss (contains the same active ingredient as Wegovy but at lower doses)
• Dosing: Once-weekly injection, typically 0.5 mg or 1 mg
• Notes: While legal to prescribe off-label, your provider must document the rationale and obtain informed consent. Insurance is more likely to cover Ozempic for diabetes than for weight loss alone. Do not combine with Wegovy or other semaglutide products.

Mounjaro (Tirzepatide) / Zepbound

• FDA approval: Mounjaro is approved for type 2 diabetes; Zepbound (same medication, higher doses) was approved for obesity in late 2023
• Dosing: Once-weekly injection, starting at 2.5 mg with titration up to 15 mg
• Expected results: Average weight loss of 15-21% of body weight in clinical trials (slightly more effective than semaglutide alone in head-to-head studies)
• Notes: Tirzepatide is a dual GIP/GLP-1 receptor agonist (unique mechanism). Like other GLP-1s, requires patient training on self-injection and proper storage.

Important Prescribing Notes

• All three are non-controlled substances: No DEA restrictions or special prescription requirements
• Telehealth-friendly: Can be prescribed remotely in compliance with federal law and most state laws
• Not diet pills: These are serious medications for chronic disease management, not quick-fix supplements
• Same contraindications: Thyroid cancer history, pregnancy, severe GI disease apply to all GLP-1s
• Side effects: Primarily gastrointestinal (nausea, vomiting, diarrhea, constipation). Usually diminish over time as the body adjusts.

Red Flags: How to Spot Questionable Telehealth Services

The explosion in demand for GLP-1 weight loss drugs has unfortunately attracted some less-than-scrupulous operators. Protect yourself by watching for these warning signs:

🚩 Guaranteed Prescriptions

Any service that promises you’ll get a prescription before you’ve even completed an evaluation is a major red flag. Legitimate providers assess each patient individually—not everyone qualifies for these medications.

🚩 Compounded or ‘Generic’ Semaglutide

As of May 2025, the FDA banned routine compounding of semaglutide for weight loss after determining the drug shortage had ended. Be extremely wary of:

• Services offering ‘compounded Wegovy’ or ‘pharmacy-made semaglutide’ at steep discounts
• Overseas or ‘gray market’ medications
• Unbranded ‘GLP-1’ injections from unclear sources

Why it matters: Compounded medications lack FDA oversight for quality, potency, and sterility. There have been reports of contamination, incorrect dosing, and adverse reactions from compounded weight loss drugs. Stick with FDA-approved, pharmacy-dispensed brand-name medications.

🚩 No Live Consultation Required

If a service allows you to get a prescription based solely on a questionnaire—with no video or phone consultation with a licensed provider—that’s a serious compliance issue in most states. A proper patient-provider relationship requires direct interaction.

🚩 No Follow-Up or Monitoring

Responsible weight loss treatment includes ongoing monitoring. If a provider writes you a 6-month or 12-month prescription with no scheduled follow-ups, they’re not meeting the standard of care. Many states explicitly require periodic check-ins.

🚩 Lack of Transparency

Be cautious if:

• The provider’s credentials or state license isn’t clearly disclosed
• There’s no physical address or clinic affiliation listed
• Pricing is hidden until after you’ve paid for a ‘consultation’
• You can’t easily contact customer support or reach your provider with questions

🚩 Pressure Tactics or Unrealistic Promises

Steer clear of services that:

• Promise dramatic weight loss in unrealistically short timeframes (‘Lose 30 pounds in 30 days!’)
• Downplay side effects or risks
• Suggest you don’t need diet and exercise changes
• Use high-pressure sales tactics or time-limited ‘special offers’

Klarity Health’s commitment: We prioritize patient safety and regulatory compliance above all else. Our providers conduct thorough evaluations, provide clear information about risks and benefits, schedule appropriate follow-ups, and only prescribe FDA-approved medications dispensed through licensed U.S. pharmacies. We accept both insurance and cash pay, with transparent pricing—and we’ll never guarantee a prescription you haven’t earned through a legitimate medical evaluation.

Privacy and Data Protection: What Telehealth Patients Should Know

Weight loss is a sensitive, personal health matter. When you share information with a telehealth provider, that data must be protected. Here’s what to know:

HIPAA Compliance

All legitimate telehealth providers must comply with the Health Insurance Portability and Accountability Act (HIPAA), which sets federal standards for protecting patient health information. This means:

• Your medical records, consultation details, and prescriptions must be stored securely
• Information cannot be shared without your consent (except as required by law)
• Video platforms used for consultations must be HIPAA-compliant (encrypted, secure)

State Privacy Laws

Some states have enacted additional consumer health privacy laws that go beyond HIPAA:

• Washington’s My Health My Data Act (2023): Imposes strict obligations on how health data (including weight, BMI, and related information) is collected, used, and shared. Telehealth providers operating in Washington must comply with specific consent and data minimization requirements.
• California Consumer Privacy Act (CCPA): Gives California residents rights to know what personal information is collected and request deletion.

What to Ask Your Provider

Before starting telehealth treatment, confirm:

• Is the platform HIPAA-compliant?
• How is my health information stored and protected?
• Who has access to my medical records?
• Will my information be sold or shared with third parties?

Klarity Health takes privacy seriously. We use secure, encrypted video platforms for all consultations, maintain HIPAA-compliant electronic health records, and never sell patient data to third parties. Your trust is essential to us.

Cost Considerations: Insurance vs. Cash Pay

The financial aspect of weight loss medication can be complex. Here’s what to expect:

Insurance Coverage

GLP-1 medications are expensive—often $900-$1,500+ per month at retail prices. Insurance coverage varies widely:

• Medicare: Generally does not cover weight loss medications (though coverage for diabetes-indicated drugs like Ozempic/Mounjaro for type 2 diabetes is standard). Some Medicare Advantage plans may offer limited coverage.
• Private insurance: Coverage is inconsistent. Some plans cover Wegovy or Zepbound for obesity with prior authorization and documentation of medical necessity. Many plans have ‘step therapy’ requirements (you must try other treatments first) or high copays.
• Medicaid: A few states have started covering GLP-1s for obesity, but it’s not universal.

Prior authorization: If your insurance covers these medications, expect to navigate a prior authorization process. Your provider will need to document:

• BMI calculation
• Weight-related comorbidities
• Previous weight loss attempts
• Medical necessity

Klarity Health works with insurance companies to handle prior authorizations on your behalf, streamlining the process.

Cash Pay Options

For patients without insurance coverage, cash pay options include:

• Manufacturer savings programs: Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Mounjaro/Zepbound) offer savings cards or patient assistance programs that can significantly reduce costs for eligible patients.
• Cash-pay telehealth pricing: At Klarity Health, we offer transparent cash pricing for consultations and prescription services. While we can’t control pharmacy costs, we help connect you with resources to minimize out-of-pocket expenses.
• Pharmacy shopping: Prices can vary by hundreds of dollars between pharmacies. GoodRx and similar services can help find the best local price.

Budgeting tip: Factor in the cost of the provider visit (consultation fees), the medication itself, and follow-up appointments when calculating total treatment costs. Weight loss medication is a long-term commitment—most people stay on treatment for at least 6-12 months, and some continue indefinitely for weight maintenance.

The Future of Telehealth Weight Loss Treatment

Telehealth for weight management is here to stay. Several trends are shaping the landscape:

Regulatory Evolution

While current DEA telehealth flexibilities for controlled substances are set to expire December 31, 2025, strong signals indicate another extension or new permanent rules are coming. For non-controlled GLP-1 drugs, the trend is clearly toward expanded access. Pending federal legislation like the TREATS Act (reintroduced in October 2025) aims to permanently allow telehealth prescribing for certain medications, reflecting Congressional support for virtual care.

At the state level, expect:

• More states granting full practice authority to NPs, reducing barriers to care
• Streamlined interstate licensure through compacts, making it easier for providers to treat patients across state lines
• Continued refinement of telehealth standards of care, ensuring quality and safety without unnecessary in-person requirements

Emerging Medications

The GLP-1 medication class continues to evolve:

• Oral GLP-1s: Rybelsus (oral semaglutide) is already available for diabetes; higher-dose versions for obesity may follow.
• Combination therapies: Research is ongoing into combinations of GLP-1s with other weight-regulating hormones.
• Longer-acting formulations: Monthly injections are in development, improving convenience.

Telehealth will remain the ideal delivery model for these treatments, offering convenient access and ongoing support.

Integration with Digital Health Tools

Expect telehealth weight loss programs to increasingly incorporate:

• Remote monitoring (connected scales, continuous glucose monitors)
• AI-powered coaching and personalized nutrition guidance
• Behavioral health integration (therapists, dietitians) within telehealth platforms
• Wearable device data to track activity, sleep, and other health metrics

Klarity Health is committed to staying at the forefront of these innovations, continuously improving how we support our patients’ weight loss journeys.

Is Telehealth Weight Loss Treatment Right for You?

Telehealth offers tremendous benefits for weight management:

✅ Convenience: No travel time, flexible scheduling, and visits from home
✅ Access: Particularly valuable in rural areas or for patients with mobility limitations
✅ Privacy: Discuss sensitive weight concerns in the comfort of your own space
✅ Continuity: Easier to maintain regular follow-ups when you’re not battling traffic or taking time off work
✅ Expert care: Access to specialized providers who focus on weight management

However, telehealth isn’t for everyone. You may be better suited to in-person care if:

• You have complex medical conditions requiring hands-on physical exams
• You prefer face-to-face interactions for building trust with providers
• You lack reliable internet access or aren’t comfortable with video technology
• You live in a state with strict in-person requirements and can’t easily satisfy them

The good news: Even if your state requires an initial in-person visit, many practices offer a hybrid model—complete the first appointment in person, then continue with convenient telehealth follow-ups.

Next Steps: Starting Your Telehealth Weight Loss Journey

Ready to explore whether telehealth weight loss treatment is right for you? Here’s how to get started:

1. Research Your State’s Requirements

Use the state-by-state table in this guide to understand any special rules in your location. If your state requires an initial in-person exam, plan accordingly—you may be able to complete that locally, then continue with telehealth.

2. Gather Your Health Information

Before your consultation, compile:

• Current height and weight
• List of current medications and supplements
• Medical history (especially thyroid, gallbladder, pancreas, or GI conditions)
• Previous weight loss attempts and their outcomes
• Any relevant lab results (A1C, metabolic panel, lipids if available)

3. Choose a Reputable Provider

Look for telehealth services that:

• Employ licensed, credentialed providers in your state
• Conduct comprehensive evaluations (not just questionnaires)
• Prescribe only FDA-approved medications from licensed U.S. pharmacies
• Offer transparent pricing (whether insurance or cash pay)
• Provide ongoing monitoring and support
• Have clear privacy policies and HIPAA-compliant systems

At Klarity Health, we check all these boxes. Our providers are experienced in weight management and licensed across multiple states. We conduct thorough video consultations, create personalized treatment plans, accept both insurance and cash pay with upfront pricing, and provide continuous support throughout your journey. We’re available when you need us, with flexible scheduling designed around your life—not the other way around.

4. Schedule Your Consultation

Most telehealth platforms make scheduling simple—often you can book online and be seen within days. During your initial visit, be honest and thorough in discussing your health history, goals, and concerns. This is your opportunity to ask questions and determine if medication is appropriate for you.

5. Commit to the Process

Weight loss medication is most effective when combined with lifestyle changes—nutrition improvements, increased physical activity, adequate sleep, and stress management. Your provider will support you, but success requires your active participation. Be prepared to:

• Attend regular follow-up appointments
• Report side effects or concerns promptly
• Track your progress (weight, measurements, how you feel)
• Make sustainable changes to eating and exercise habits
• Be patient—healthy weight loss is gradual (1-2 pounds per week is typical and sustainable)

Conclusion: Access to Care in the Digital Age

The ability to access weight loss medication through telehealth represents a significant advancement in healthcare accessibility. For millions of Americans struggling with obesity—a chronic disease associated with serious health risks including type 2 diabetes, heart disease, and certain cancers—telehealth removes barriers that previously prevented many from getting help.

Yes, you can legally and safely obtain GLP-1 weight loss medications through telehealth in most states, with appropriate medical oversight and follow-up. Federal law permits it for non-controlled medications, and the majority of states have embraced telemedicine as a valid care delivery model. While some states impose additional requirements (like initial in-person exams), the overall trend is toward expanded access with appropriate safeguards.

The key is working with legitimate, compliant providers who prioritize your safety and long-term success—not quick profits. Avoid services that cut corners, offer guarantees, or sell questionable compounded products. Instead, choose established telehealth platforms with transparent practices and licensed providers.

If you’re ready to take control of your weight and health, telehealth offers a convenient, effective pathway forward. With the right support, evidence-based medication, and commitment to lifestyle change, sustainable weight loss is within reach—no matter where you live.

Ready to get started? Klarity Health is here to help. Our experienced providers offer comprehensive telehealth weight loss consultations, personalized treatment plans, and ongoing support—all with the convenience of virtual care. We accept insurance and offer transparent cash-pay options. Schedule your consultation today and take the first step toward a healthier you.

Frequently Asked Questions

Can I get Wegovy or Ozempic through telehealth without an in-person visit?

In most states, yes. Federal law does not require an in-person exam for GLP-1 medications since they’re not controlled substances. However, a few states (Arkansas, Georgia, New Jersey, South Carolina, Virginia, and some others) require an initial in-person physical exam. Check your state’s specific requirements.

Will my insurance cover telehealth visits for weight loss medication?

Many insurance plans now cover telehealth visits at the same rate as in-person visits. Coverage for the medications themselves varies widely—some plans cover Wegovy/Zepbound with prior authorization, while others don’t cover weight loss drugs at all. Klarity Health can help verify your coverage and handle prior authorization paperwork.

How long does a telehealth weight loss consultation take?

Initial consultations typically last 20-30 minutes. Your provider will review your medical history, discuss your weight loss goals, assess eligibility for medication, and create a treatment plan. Follow-up visits are usually shorter (10-15 minutes).

Are compounded semaglutide products safe?

The FDA banned most compounding of semaglutide in May 2025 due to safety concerns. Stick with FDA-approved brand-name medications (Wegovy, Ozempic, Mounjaro, Zepbound) dispensed through licensed U.S. pharmacies. Compounded versions lack FDA quality oversight and have been associated with contamination and dosing errors.

How much weight can I expect to lose with GLP-1 medications?

Clinical trials show average weight loss of 15-20% of starting body weight over 68 weeks with Wegovy, and slightly more with tirzepatide (Mounjaro/Zepbound). Individual results vary—some people lose more, some less. Weight loss is gradual and most effective when combined with lifestyle changes.

Can I switch from Ozempic to Wegovy or vice versa?

Both contain semaglutide—the same active ingredient—so you should not take them simultaneously. Switching from one to the other is medically straightforward, but the decision should be made with your provider based on FDA approval, insurance coverage, and dosing needs.

What if I experience side effects?

GI side effects (nausea, vomiting, diarrhea, constipation) are common, especially when starting or increasing doses. Most diminish over time. Contact your provider if side effects are severe or persistent—they may adjust your dose or provide strategies to manage symptoms. Seek immediate medical attention for signs of pancreatitis (severe abdominal pain), gallbladder problems, or allergic reactions.

How long will I need to take weight loss medication?

Weight loss medications are typically long-term treatments. Most people continue for at least 6-12 months during active weight loss, and many remain on a maintenance dose indefinitely to prevent weight regain. This decision should be made collaboratively with your provider based on your results and health status.

Research Citations

1. DEA Announcement (Nov 2024) – ‘DEA and HHS Extend Telemedicine Flexibilities through 2025.’ www.dea.gov, November 15, 2024.

2. Axios News – ‘COVID-era telehealth prescribing extended.’ www.axios.com, November 18, 2024.

3. McDermott Law – ‘DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025.’ www.mwe.com, November 18, 2024.

4. Goodwin Law Alert – ‘The Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs.’ www.goodwinlaw.com, March 27, 2024.

5. Reuters News – ‘Hims & Hers to cut 4% of workforce amid ban on weight-loss drug copies.’ www.reuters.com, May 30, 2025.

Verified as of December 17, 2025. Federal telehealth rules for controlled substances are temporary (set to expire December 31, 2025); an additional extension or new rule is expected. State laws continue to evolve—watch for changes in 2026, including pending NP practice authority bills and potential federal legislation like the TREATS Act. FDA oversight on compounded GLP-1 medications tightened in 2025; ensure compliance with current FDA guidance.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid